Nabriva Therapeutics PLC (STU:NTY)
€ 1.25 0.02 (1.63%) Market Cap: 2.76 Mil Enterprise Value: 1.62 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 39/100

Nabriva Therapeutics plc Complete Response Letter from FDA on NDA Conference Call Transcript

May 01, 2019 / 12:00PM GMT
Release Date Price: €665
Operator

Good day, ladies and gentlemen. Welcome to the Nabriva Therapeutics Conference Call. (Operator Instructions) As a reminder, this call is being recorded.

I would now like to introduce your host for today's conference, David Garrett, Vice President, Corporate Controller and Head of Investor Relations. Please go ahead.

David Garrett
Nabriva Therapeutics AG - Head of IR, VP & Corporate Controller

Thank you, and good morning, everyone. Welcome to Nabriva's conference call to discuss the Complete Response Letter from the FDA for CONTEPO. A press release summarizing the Complete Response Letter was issued yesterday and can be found at www.nabriva.com.

Before we begin, I'd like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of the date of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot